195 related articles for article (PubMed ID: 32970335)
1. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
[TBL] [Abstract][Full Text] [Related]
2. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.
Yegutkin GG; Auvinen K; Rantakari P; Hollmén M; Karikoski M; Grénman R; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2015 Feb; 45(2):562-73. PubMed ID: 25402681
[TBL] [Abstract][Full Text] [Related]
3. Different role of CD73 in leukocyte trafficking via blood and lymph vessels.
Ålgars A; Karikoski M; Yegutkin GG; Stoitzner P; Niemelä J; Salmi M; Jalkanen S
Blood; 2011 Apr; 117(16):4387-93. PubMed ID: 21346249
[TBL] [Abstract][Full Text] [Related]
4. Ecto-5'-nucleotidase, CD73, is an endothelium-derived hyperpolarizing factor synthase.
Ohta M; Toyama K; Gutterman DD; Campbell WB; Lemaître V; Teraoka R; Miura H
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):629-36. PubMed ID: 23288168
[TBL] [Abstract][Full Text] [Related]
5. CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans.
Joolharzadeh P; St Hilaire C
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):339-348. PubMed ID: 30676071
[TBL] [Abstract][Full Text] [Related]
6. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
7. The volatile anesthetic isoflurane induces ecto-5'-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury.
Kim M; Ham A; Kim JY; Brown KM; D'Agati VD; Lee HT
Kidney Int; 2013 Jul; 84(1):90-103. PubMed ID: 23423261
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD73 slows down migration of skin dendritic cells, affecting the sensitization phase of contact hypersensitivity reactions in mice.
Neuberger A; Ring S; Silva-Vilches C; Schrader J; Enk A; Mahnke K
J Dermatol Sci; 2017 Sep; 87(3):292-299. PubMed ID: 28743609
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD73 therapy impairs tumor angiogenesis.
Allard B; Turcotte M; Spring K; Pommey S; Royal I; Stagg J
Int J Cancer; 2014 Mar; 134(6):1466-73. PubMed ID: 23982901
[TBL] [Abstract][Full Text] [Related]
10. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes.
Takedachi M; Qu D; Ebisuno Y; Oohara H; Joachims ML; McGee ST; Maeda E; McEver RP; Tanaka T; Miyasaka M; Murakami S; Krahn T; Blackburn MR; Thompson LF
J Immunol; 2008 May; 180(9):6288-96. PubMed ID: 18424752
[TBL] [Abstract][Full Text] [Related]
11. Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).
Minor M; Alcedo KP; Battaglia RA; Snider NT
Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1079-C1092. PubMed ID: 31461341
[TBL] [Abstract][Full Text] [Related]
12. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
13. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
14. The volatile anesthetic isoflurane increases endothelial adenosine generation via microparticle ecto-5'-nucleotidase (CD73) release.
Kim M; Ham A; Kim KY; Brown KM; Lee HT
PLoS One; 2014; 9(6):e99950. PubMed ID: 24945528
[TBL] [Abstract][Full Text] [Related]
15. Production of Extracellular Adenosine by CD73
Silva-Vilches C; Ring S; Schrader J; Clausen BE; Probst HC; Melchior F; Schild H; Enk A; Mahnke K
J Invest Dermatol; 2019 Mar; 139(3):541-551. PubMed ID: 30393085
[TBL] [Abstract][Full Text] [Related]
16. CD73
Ko MK; Shao H; Kaplan HJ; Sun D
Front Immunol; 2020; 11():601272. PubMed ID: 33343573
[TBL] [Abstract][Full Text] [Related]
17. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
18. IFN-beta protects from vascular leakage via up-regulation of CD73.
Kiss J; Yegutkin GG; Koskinen K; Savunen T; Jalkanen S; Salmi M
Eur J Immunol; 2007 Dec; 37(12):3334-8. PubMed ID: 18034430
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
[TBL] [Abstract][Full Text] [Related]
20. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
Wang L; Fan J; Thompson LF; Zhang Y; Shin T; Curiel TJ; Zhang B
J Clin Invest; 2011 Jun; 121(6):2371-82. PubMed ID: 21537079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
